NASDAQ:TYRA

Tyra Biosciences (TYRA) Stock Price, News & Analysis

$15.52
-0.48 (-3.00%)
(As of 10:16 AM ET)
Today's Range
$14.87
$16.15
50-Day Range
$14.45
$20.00
52-Week Range
$10.38
$20.67
Volume
7,998 shs
Average Volume
129,215 shs
Market Capitalization
$815.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

Tyra Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
41.8% Upside
$22.00 Price Target
Short Interest
Bearish
14.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$298,165 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.89) to ($2.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.67 out of 5 stars

Medical Sector

837th out of 907 stocks

Pharmaceutical Preparations Industry

394th out of 422 stocks

TYRA stock logo

About Tyra Biosciences Stock (NASDAQ:TYRA)

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

TYRA Stock Price History

TYRA Stock News Headlines

Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
TYRA Mar 2024 20.000 call
TYRA Mar 2024 20.000 put
Wedbush stays Outperform on Tyra Biosciences after pipeline updates
Tyra S. Carter
See More Headlines
Receive TYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
4/25/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TYRA
Fax
N/A
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.00
High Stock Price Target
$28.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+37.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-69,130,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.74 per share

Miscellaneous

Free Float
42,860,000
Market Cap
$840.32 million
Optionable
Optionable
Beta
1.12
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Todd Harris Ph.D. (Age 45)
    Co-Founder, President, CEO, Secretary, Treasurer & Director
    Comp: $903.33k
  • Mr. Daniel Bensen (Age 48)
    Co-Founder & COO
    Comp: $630.8k
  • Mr. Ali D. Fawaz J.D.
    General Counsel & Secretary
  • Mr. Alan Fuhrman (Age 67)
    Chief Financial Officer
  • Dr. Robert L. Hudkins Ph.D. (Age 68)
    Chief Technology Officer
  • Dr. Ronald V. Swanson Ph.D. (Age 60)
    Chief Scientific Officer
    Comp: $536.19k
  • Ms. Sarah Honig
    Vice President of Corporate Development & Strategy
  • Dr. Hiroomi Tada M.D. (Age 60)
    Ph.D., Chief Medical Officer
    Comp: $519.65k
  • Dr. Piyush R. Patel Ph.D. (Age 58)
    Chief Development Officer
  • Amy Conrad
    Investor Contact

TYRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Tyra Biosciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TYRA shares.
View TYRA analyst ratings
or view top-rated stocks.

What is Tyra Biosciences' stock price target for 2024?

3 brokerages have issued 12-month price objectives for Tyra Biosciences' shares. Their TYRA share price targets range from $15.00 to $28.00. On average, they anticipate the company's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 41.8% from the stock's current price.
View analysts price targets for TYRA
or view top-rated stocks among Wall Street analysts.

How have TYRA shares performed in 2024?

Tyra Biosciences' stock was trading at $13.85 at the beginning of 2024. Since then, TYRA stock has increased by 12.1% and is now trading at $15.52.
View the best growth stocks for 2024 here
.

When is Tyra Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our TYRA earnings forecast
.

How were Tyra Biosciences' earnings last quarter?

Tyra Biosciences, Inc. (NASDAQ:TYRA) announced its quarterly earnings results on Tuesday, March, 19th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.05.

When did Tyra Biosciences IPO?

Tyra Biosciences (TYRA) raised $100 million in an initial public offering on Wednesday, September 15th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share.

Who are Tyra Biosciences' major shareholders?

Tyra Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fishman Jay A Ltd. MI (0.03%). Insiders that own company stock include Boxer Capital, Llc, Daniel Bensen, Mva Investors, Llc and Todd Harris.
View institutional ownership trends
.

How do I buy shares of Tyra Biosciences?

Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TYRA) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners